NDC 63323-669-01 - Potassium Chloride
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 63323-669
- Requested NDC
- 63323-669-01
- Package NDCs from labels
- 63323-669-01, 63323-669-10
- Manufacturer
- Fresenius Kabi USA, LLC | HP Halden Pharma AS
- Effective date
- 2024-05-08
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Potassium Chloride - Fresenius Kabi USA, LLC | HP Halden Pharma AS | Fresenius Kabi USA, LLC | HP Halden Pharma AS | 2024-05-08 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 63323-669-01 | Potassium Chloride | 1000 mL in 1 BAG | INJECTION, SOLUTION | 1000 | 4 | |
| 63323-669-10 | Potassium Chloride | 10 in 1 CASE | INJECTION, SOLUTION | 10 | 4 |
DailyMed Dashboard NDC Coverage#
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 63323-669-01 | ML - Milliliter | 63323-669 | df69b3e2-d314-4b8a-b889-22a29d258378 | 1 | 2022-11-07 |
| 63323-669-10 | ML - Milliliter | 63323-669 | a4d22102-39bb-45a1-afb0-29254d692766 | 1 | 2022-11-07 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| POTASSIUM CHLORIDE | POTASSIUM CHLORIDE | Lupin Pharmaceuticals,Inc. | 28c49165-d8c9-443a-b000-953b8e1ec55c | 2020-11-20 | Warnings, Adverse reactions | 660YQ98I10 |
| Lactated Ringers | SODIUM CHLORIDE, SODIUM LACTATE, POTASSIUM CHLORIDE, AND CALCIUM CHLORIDE | Asclemed USA, Inc. | afac6cc5-1ced-4639-b6f6-86f40ef5c30e | 2020-10-29 | Warnings, Adverse reactions | 660YQ98I10 |
| POTASSIUM CHLORIDE IN DEXTROSE | DEXTROSE AND POTASSIUM CHLORIDE | B. Braun Medical Inc. | e5bbb3e1-ab50-4ec7-a2b4-ce4091712e23 | 2020-07-31 | Warnings, Adverse reactions | 309783 660YQ98I10 |
| Cardioplegic | CALCIUM CHLORIDE, MAGNESIUM CHLORIDE, POTASSIUM CHLORIDE AND SODIUM CHLORIDE | Baxter Healthcare Corporation | 1fd50ce5-2799-4c26-81da-02cf0578dd9e | 2020-06-11 | Warnings, Adverse reactions | 660YQ98I10 |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | ee831456-5962-4d5e-ad0c-69ab85860453 | 2020-06-03 | LX22YL083G | |
| LACTATED RINGERS AND DEXTROSE | SODIUM CHLORIDE, SODIUM LACTATE, POTASSIUM CHLORIDE, CALCIUM CHLORIDE, AND DEXTROSE MONOHYDRATE | HF Acquisition Co LLC, DBA HealthFirst | a62cf623-9b8a-37e0-e053-2995a90add5b | 2020-05-21 | Warnings, Adverse reactions | 660YQ98I10 LX22YL083G |
| Isolyte S | SODIUM CHLORIDE, SODIUM GLUCONATE, SODIUM ACETATE, POTASSIUM CHLORIDE, AND MAGNESIUM CHLORIDE | B. Braun Medical Inc. | 7e8fe27f-ff82-48c1-9bf6-3c589c8e985d | 2020-05-14 | Warnings, Adverse reactions | 660YQ98I10 |
| DEXTROSE AND SODIUM CHLORIDE | DEXTROSE MONOHYDRATE, SODIUM CHLORIDE | Fresenius Kabi USA, LLC | b825c9c4-f2fb-4a4a-9d8c-fb020ad07e93 | 2020-04-30 | Warnings, Adverse reactions | LX22YL083G |
| Potassium Chloride | POTASSIUM CHLORIDE | Genus Lifesciences Inc. | 23d818e7-c076-40de-8dc1-0b51ba4be96a | 2020-04-28 | Warnings, Adverse reactions | 660YQ98I10 |
| Potassium Chloride | POTASSIUM CHLORIDE | Lupin Pharmaceuticals,Inc. | 1bbacdbb-91fa-4897-a00c-1b293de27b83 | 2020-04-27 | Warnings, Adverse reactions | 660YQ98I10 |
| Potassium Chloride | POTASSIUM CHLORIDE | Mylan Pharmaceuticals Inc. | c64ed4c0-1e27-42b3-9625-fb4e0d31e271 | 2020-04-15 | Warnings, Adverse reactions | 660YQ98I10 |
| Dextrose | DEXTROSE MONOHYDRATE | Baxter Healthcare Company | 7de48bdb-9a05-4f2a-bbff-dcfeb284ca6e | 2020-02-27 | Warnings, Adverse reactions | LX22YL083G |
| Dextrose and Electrolyte No. 48 | SODIUM LACTATE, POTASSIUM CHLORIDE, MAGNESIUM CHLORIDE, MONOBASIC POTASSIUM PHOSPHATE, SODIUM CHLORIDE AND DEXTROSE MONOHYDRATE | Baxter Healthcare Company | b283a454-0c20-4fbf-92d3-dae1f3cd3cad | 2020-02-13 | Warnings, Adverse reactions | 660YQ98I10 LX22YL083G |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | e41adb4e-06fb-4141-ba55-50b043f3c9da | 2019-11-19 | LX22YL083G | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 14445dfd-6041-40cd-a043-3f4da6bcb9c1 | 2019-11-18 | LX22YL083G | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 2557199a-5f60-49d8-b093-1e0700211243 | 2019-11-18 | LX22YL083G | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 794f724c-87f0-49c1-9b26-c9e491978313 | 2019-11-18 | LX22YL083G | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 5c7d3287-883a-459b-9214-074a583c8a59 | 2019-11-18 | LX22YL083G | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 448a1dc5-7a98-4b2f-82af-4b92de05cfc3 | 2019-11-18 | LX22YL083G | |
| Plasma-Lyte A | SODIUM CHLORIDE, SODIUM GLUCONATE, SODIUM ACETATE, POTASSIUM CHLORIDE AND MAGNESIUM CHLORIDE | Baxter Healthcare Corporation | 6ec9e61c-2c26-402f-8604-f446b2e34058 | 2019-08-05 | Warnings, Adverse reactions | 660YQ98I10 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.